You are here: Industry Insights > Series B

News List

ArcScan, Inc. Signs Definitive Agreement for $11.15 Million Preferred Series B Investment with Shanghai Haohai Biological Technology Ltd. prnasia
July 22, 2021
ArcScan, Inc. announces the execution of a Stock Purchase Agreement with Shanghai Haohai Biological Technology Ltd. that will result in a $11.15 million Preferred Series B investment into ArcScan, Inc.
Cambridge start-up PhoreMost raises £33m to progress PLK1 programme pharmatimes
March 26, 2021
Cambridge, UK-based PhoreMost has announced the closing of a £33m Series B investment round from new and existing investors.
Stelis concludes $195 million Series B and Series C fund raise expresspharma
March 19, 2021
Stelis Biopharma (Stelis) announced that it has successfully concluded its Series B and Series C fund raise for a cumulative amount of $195 million.
Numab closes $23.6m Series B round led by Asian investors pharmaceutical-technology
March 11, 2020
Swiss biotech Numab has raised CHF22m ($22.7m) in a Series B financing round, which attracted multiple new investors from Asia, including 3SBio, Mitsubishi UFJ Capital and Eisai, as well as a company board member Dr Daniel Vasella.
BlackStone Therapeutics closes $76 m Series B financing biospectrumasia
June 16, 2019
BlackThorn also announced two appointments to its executive management team: Jane Tiller, MBChB, FRCPsych, as chief medical officer, and Laura Hansen, Ph.D., as vice president, corporate affairs. Dr. Tiller, who brings extensive clinical psychiatry and dr
Emergency EEG maker Ceribell raises $35M in series B round fiercebiotech
September 27, 2018
The system's headband includes a “brain stethoscope” feature that converts EEG signals to sound.
RSP Systems Secures Series B Funding to Drive its Non-Invasive Glucose Monitor b3cnewswire
June 20, 2018
RSP Systems A/S, the non-invasive diagnostics company, announces that it has completed the first closing of a Series B funding round amounting to €6.5 million. The round remains open for a second closing due to strong interest.